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Introduction
Pulmonary arterial hypertension (PAH) is characterized by dysregulated pulmonary vascular remodeling that leads to an increase in pulmonary vascular resistance, right ventricular hypertrophy, dysfunction and uncompensated right heart failure, and ultimately death. 1 Vascular remodeling occurs as a result of pulmonary vascular endothelial dysfunction, PASMC proliferation and migration, medial hypertrophy, inflammation, and thrombosis in situ leading to the formation of plexiform lesions, which are a hallmark of the disease. 2 3 These remodeled vessels, together with an imbalance in vasodilators and vasoconstrictors, contribute to increase pulmonary vascular resistance, which, in turn, strains and remodels the right heart. Despite our understanding of these pathobiological processes, pharmacotherapies to treat the disease are limited and survival outcomes have improved little over the past few decades. 4 In vascular smooth muscle cells, SERCA2a modulates calcium homeostasis. Under basal conditions, SERCA2a sequesters calcium in the endoplasmic reticulum; when SERCA2a is downregulated, intracellular calcium [Ca 2+ ]i levels are increased. In rat vascular injury models, SERCA2a expression is downregulated in the vascular media leading to increased [Ca 2+ ]i and activation of calcineurin (protein phosphatase 2B)/cytoplasmic nuclear factor of activated T cells (NFAT) signaling to stimulate vascular smooth muscle cell proliferation and promote neointima formation. 5 Similar findings have also been observed in human coronary artery smooth muscle cells in vitro and balloon-injured human internal mammary arteries ex vivo. 6, 7 Akin to what is observed in the systemic vasculature, there is evidence to indicate that SERCA2a is downregulated in PAH. In PASMCs isolated from PAH patients and animal models of PAH, [Ca 2+ ]i levels are elevated and this stimulates PASMC proliferation and migration.
Furthermore, PASMCs isolated from patients with idiopathic PAH demonstrate increased understanding of these pathobiological processes, pharmacotherapies to treat the e d dis is sea a ase s se a a are re re imited and survival outcomes have improved little over the past few decades. 4 I In In v v vas as scu ula la ar r r s smooth muscle cells, SERCA A A2a 2a 2 modulates ca alc lc cium m m h ho homeostasis. Under basal co on nd nditions, SE ERC RC RCA2 A2 A2a a a se e equ qu q es es este te ters rs c c ca al alci cium um m in n n th h he e en nd d dopl pl pla as asm m mic c re ret ti tic cu ulu lum m m; w whe he hen n n SE SE ERC RC RCA A2 A a a a is is do down wn wnre re regu gu gula la ate te ted, d, i i int nt tra race cell ll lul ular ar c c cal al alci ci cium um um [ [Ca Ca Ca ]i -dependent NFAT activation is associated with vascular remodeling in PAH. [8] [9] [10] Thus, strategies to maintain SERCA2a expression and regulate [Ca 2+ ]i should offer a therapeutic benefit in PAH by limiting pulmonary vascular cell proliferation and, thereby, vessel remodeling.
Gene transfer of SERCA2a has demonstrated in vivo therapeutic efficacy in small and large animal models of vascular injury. Forced expression of SERCA2a in vascular smooth muscle cells restores sarco/endoplasmic reticulum Ca 2+ handling, decreases [Ca 2+ ]i, and inhibits NFAT transcriptional activity to limit proliferation, migration, and neointima formation.
SERCA2a gene transfer has also been shown to abrogate endothelial dysfunction by increasing endothelial nitric oxide synthase (eNOS) expression and activity. 5, 7 SERCA2a gene transfer using adeno-associated virus serotype 1 (AAV1.SERCA2a) has been validated extensively in the ventricular myocardium and shown to improve left ventricular systolic function and ventricular remodeling in rat and swine preclinical models of heart failure and in a phase 2 clinical trial of patients with New York Heart Association Stage III/IV congestive heart failure. 11 The therapeutic potential of SERCA2a gene transfer to target pulmonary vascular dysfunction in PAH has not been tested to date. We, therefore, hypothesized that SERCA2a is downregulated in pulmonary arterioles in PAH and that gene transfer of SERCA2a via intratracheal administration of aerosolized AAV1.SERCA2a would provide selective gene transfer to the pulmonary circulation to prevent or ameliorate pulmonary vascular remodeling and right ventricular myocardial dysfunction in PAH.
Methods
Please refer to the expanded Methods section in the online-only Data Supplement.
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Human lung tissue samples
Lung tissue specimens were obtained at the time of lung transplantation from 8 patients with idiopathic PAH, and at the time of thoracic surgery (lobectomy or pneumonectomy for localized lung cancer) from 5 patients without PAH that served as controls. Preoperative echocardiography was performed in the control patients to rule out pulmonary hypertension. Lung tissue from the control patients was collected at a site remote from tumor foci. The study was approved by the local ethics committee (Comité de Protection des Personnes, CPP Ile de France VII, Le Kremlin Bicêtre, France) and patients gave informed consent.
Cell culture
Human pulmonary artery smooth muscle cells (PASMC) and pulmonary artery endothelial cells (PAEC) were purchased from Lonza, Inc. (Allendale, NJ). PASMC were cultured in SmBM medium supplemented with 5% fetal bovine serum (FBS) and SmGM-2 SingleQuots (Lonza).
PAEC were grown in EBM-2 medium supplemented with 5% fetal bovine serum supplemented with EGM-2 SingleQuots (Lonza). Cells were grown in 5% CO 2 at 37°C and passaged at confluence.
Adenovirus and adeno-associated virus (AAV1) vectors
Ad-SERCA2a encoding human SERCA2a and green fluorescence protein (GFP) under control of the cytomegalovirus (CMV) promoter; 12 Ad-Gal, encoding -Galactosidase and GFP under control of the CMV promoter; 12 and Ad-VIVIT, encoding the NFAT competing peptide VIVIT and GFP under control of the CMV promoter were produced as described previously. 13, 14 Cells were infected with adenovirus at 100 pfu/cell. The efficiency of infection was assessed by GFP fluorescence.
Human AAV1-SERCA2a and AAV1. Gal were produced as described previously. 15 The
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rAAV1.SERCA2a vector used in this study contains an AAV serotype 1 viral capsid and a single-stranded ~4.5 kb DNA containing the human SERCA2a cDNA driven by a CMV immediate-early promoter/enhancer, a hybrid intron, and a bovine growth hormone polyadenylation signal, all flanked by 145 nt AAV2 inverted terminal repeat sequences necessary for replication and packaging of the vector DNA in the capsid. The vector was manufactured using standard calcium phosphate transfection methods in adherent 293 cells. Three plasmids were used, one containing helper functions from adenovirus, one containing the AAV rep2 and cap1
genes, and the third containing the vector genome. AAV1. Gal was constructed in a similar fashion using the -Galactosidase gene.
Rat monocrotaline-PAH model
All animal experiments were approved by the Icahn School of Medicine at Mount Sinai institutional animal use and care committee and were in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Adult male Sprague-Dawley rats (Charles River, MA) weighing 350-400 g were fed standard chow and administered an intraperitoneal injection of monocrotaline (MCT) 60 mg/kg (Sigma-Aldrich, St. Louis, MO) (MCT group) or 0.9% saline as a control group (sham, n=6). In the treatment protocol, 15 days after the MCT or vehicle control injection, rats from the MCT group (n=30) were randomized to one of three treatment groups: saline (n =10); AAV1. gal (3.5 x10 11 vg/ml, n=10) or AAV1.SERCA2a (3.5x10 11 vg/ml, n=10). Treatments were aerosolized in 300 μl for single dose intratracheal delivery using an IA-1C Microsprayer (PennCentury, Wyndmoor, PA). In the prevention protocol, immediately after MCT or vehicle control (n=6) injection, rats were randomized into the three treatment groups: Saline (n=15); AAV1.SERCA2a (n=15) or AAV1. gal (n=6) delivered as described for the treatment protocol. Hemodynamic studies were
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Right and left heart hemodynamic studies
Rats were anesthetized with 1% isofluorane, intubated via a tracheotomy, and mechanically ventilated (tidal volume=10 mL/kg; respiratory rate=30 breaths per minute). The thoracic cavity was opened using a midsternal approach, a Scisense catheter was inserted directly into the right or left ventricle and an ultrasonic flow probe (flow probe 2.5S176; Transonic Systems Inc., Ithaca, NY) was placed on the ascending root of the aorta. The heart rate, mean pulmonary artery pressure (mPAP), aortic systolic arterial pressure, right and left ventricular end-systolic and diastolic pressures (RVESP, LVESP, RVEDP and LVEDP, respectively) were measured directly. Hemodynamic data were recorded using a Scisense P-V Control Unit (Scisense, Ontario, Canada).
Statistical Analysis
Results are presented as mean±SEM. Normality of the data was assumed based on prior study of the outcome variables subjected to Shapiro-Wilk testing. 16 Data were analyzed using an unpaired t test for comparisons between two means or a one-way ANOVA with the Bonferonni correction for comparisons between >2 means. Data comparison between the AAV1.SERCA2a and AAV1. gal groups was analyzed by using a post-hoc Tukey test. P<0.05 was considered significant. Statistical analysis was performed using GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA).
Results

SERCA2a expression is decreased in human PAH
To determine if SERCA2a expression is decreased in PAH, we examined pulmonary vessels and To To u u und nd nder erst st tan an and d th th he ro role le e o o of f SE SE ERC RC RCA2 A2 A2a a a in in n p p pul ul ulmo m mona na n ry ry ry v v vas s scu cu ula la lar r r re re emo mo mode de deli li l ng ng ng, we we f fir ir rst st e e exa xa xam mi ine ne ed d t th the e effect of modu du ula la ati ti ing ng ng S S SER ER E CA CA CA2a 2a 2 e e exp xp xpre re r ss ss sio io ion n n on on on PA PA PASM SM SMC C pr pr p ol ol o if if i er er erat at atio ion n n an an and d d mi mi migr grat at atio io ion. n. n. P P PAS A MC PASMCs: SERCA2a was undetectable in non-infected or Ad. Gal-infected cells but highly expressed in Ad.SERCA2a-infected PASMCs ( Figure 2B ). Increased SERCA2a expression was associated with a significant decrease in calcineurin/protein phosphatase 2B (PP2B) and Cyclin D1 expression compared to control or Ad. Gal-infected cells ( Figure 2B) . Similarly, inhibition of PP2B signaling by adenovirus-mediated expression of VIVIT, a peptide that competes with NFAT for binding to PP2B, decreased PASMC proliferation significantly, suggesting that SERCA2a inhibits proliferation by regulating NFAT activity (Figure 2A) . Therefore, we assessed the effect of SERCA2a on NFAT transcriptional activity. Compared to Ad. Galinfected or non-infected cells, SERCA2a overexpression decreased NFAT transcriptional activity by 2.5-fold (p=0.0008) ( Figure 2C ). We next examined the effect of SERCA2a on STAT3, which has been shown to regulate NFAT and is activated in PAH. 10 Overexpression of SERCA2a decreased phosphorylation and activation of STAT3 ( Figure 2D ). Thus, these findings indicate that SERCA2a inhibits PASMC proliferation through a mechanism that involves decreased activation of STAT3 and NFAT.
SERCA2a limits proliferation and migration of PAECs and restores activation of eNOS
As remodeled vessels demonstrate intimal hypertrophy, we also examined the effect of We first assessed the efficiency of AAV1-mediated gene transfer by performing X-Gal staining to corroborate transduction in lung tissue harvested 30 days after the intratracheal delivery of AAV1. Gal in MCT rats. -Galactosidase was expressed abundantly throughout the intima and media of small pulmonary arteries indicating successful gene transfer to the pulmonary vessels using AAV1 and aerosolized intratracheal delivery. -Galactosidase was also detected in bronchial smooth muscle cells (Supplemental Figure 3A) . We also examined SERCA2a mRNA levels and protein expression in the lungs at the end of the 30-day treatment period; human SERCA2a mRNA levels were detected only in MCT-PAH rats randomized to aerosolized AAV1.SERCA2a (Supplemental Figure 3B) . Next, SERCA2a protein levels were assessed in lung homogenates using an antibody that recognized both the human and the rat 
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We We e f f fir i irst st a a ass ss ses ess s sed d d th the e ef ef effi fi fici ci cien en ency cy y o o of f f AA AA AAV1 V1 V -m -m -m p p per er e fo fo orm rm rmin n ng g X-X-X Ga Ga Gal l l ed ed dia ia ate te ted d d ge ge ene ne ne tra ra rans ns n f f fer r by by y taining to co orr rr rrob ob o or or orat at a e e e tr tr t an n nsd sd sduc uc ucti ti tion on on i in lu lu lung ng ng t t tis is issu su s e e e ha ha harv rves es este te ted d d 30 30 0 d d day ay ys s s af af afte te ter r r th th the e in in intr tr trat at atra ra rach c eal SERCA2a isoform. SERCA2a expression was downregulated in MCT-PAH rats treated with aerosolized saline or AAV1. Gal but was highly expressed in AAV1.SERCA2a-treated MCT-PAH rats ( Figure 3B ). These findings were confirmed by immunofluorescent staining of remodeled pulmonary arteries. SERCA2a expression was downregulated in MCT-PAH rats treated with saline or AAV1. Gal but detectable in rats treated with AAV1.SERCA2a ( Figure   3C ). These findings confirm that SERCA2a is downregulated in pulmonary vessels from rats with MCT-induced PAH and intratracheal aerosol delivery of AAV1.SERCA2a is sufficient to transduce pulmonary vessels and increase pulmonary arteriole SERCA2a expression.
To determine the effect of increased pulmonary vascular SERCA2a expression on pulmonary hemodynamics, we measured pulmonary artery pressures on day 45. Compared to the Sham rats, MCT-PAH rats treated with aerosolized saline or AAV1. Gal demonstrated increased pulmonary artery systolic (PAs), pulmonary artery diastolic (PAd), and mean pulmonary artery In PAH, pulmonary vascular remodeling is characterized by apoptosis-resistant smooth muscle cells that contribute to vessel hypertrophy. 20 We, therefore, next sought to determine if 
Right ventricular remodeling in PAH is improved by vascular SERCA2a gene transfer
In PAH, elevated pulmonary vascular pressures result in right ventricular (RV) hypertrophy and ultimately the development of right heart failure. As it is known that SERCA2a expression is downregulated in the left ventricle (LV) in heart failure, 18, 19 we first examined SERCA2a protein Gi Gi ive ve v n n n th th t at at A A AAV AV AV1 1.SE SERC RC RCA2 A a a a ha ha ad d d th th ther era ap apeu eu euti ti tic c ef ef effi fic ca cacy cy c i in n n es es est t tabl bl blis ishe he ed d d PA PA AH H, H, w w we e al al a so so o s s sou u ugh gh ht t to to o determine wh whet et ethe he her r r ge ge g ne ne ne tra ra ans ns nsfe fer r r of of o S S SE ERC RC RCA2 A2 A2a a a vi vi v a a a AA AA AAV1 V1 V1.S S SER ER ERCA CA CA2a 2a 2a c c cou ou ould ld ld p p pre re eve ve vent nt nt t t the he h AAV1.SERCA2a also prevented the increase in pulmonary vascular resistance observed in AAV1. Gal-treated rats (0.25±0.05 vs. 0.08±0.01 mmHg*min/ml, p<0.001). Similarly, treatment with AAV1.SERCA2a prevented RVH as evidenced by a decrease in RV weight and RV systolic pressure compared to the saline-or AAV1. Gal-treated groups (Figure 8D, E) . As noted in the treatment protocol, there was no difference between treatment groups with respect to LV filling pressures or weight (Supplemental Figure 6) . Thus, a single intratracheal injection of aerosolized AAV1.SERCA2a can prevent PAH in the MCT-PAH rat model.
Discussion
This study provides the first evidence that SERCA2 protein expression levels are downregulated in lung samples from patients with PAH and in cultured proliferating human PASMC and PAECs. Similarly, in the rat MCT model of PAH, we observed a decrease in pulmonary vascular SERCA2a protein expression 45 days after MCT injection. Impaired SERCA2a activity resulting from a decrease in SERCA2a expression may therefore be implicated in the pathogenesis of PAH. Herein, we show that a single intratracheal delivery of aerosolized AAV1.SERCA2a has therapeutic efficacy in PAH. Four weeks after gene transfer, the SERCA2a mRNA transcript was still detectable in the pulmonary tissue of animals transduced with SERCA2a, demonstrating persistent transgene expression. In addition, AAV1.SERCA2a gene transfer reduced the severity of pulmonary vascular remodeling accompanied by anti-inflammatory and anti-fibrotic effects.
Pulmonary vascular gene transfer of AAV1.SERCA2a also diminished RV hypertrophy and fibrosis and prevented the decrease in RV SERCA2a expression seen in control animals with RVH and failure, likely as a result of the reduction in right heart load.
In PAH, hypertensive pulmonary vascular disease and pulmonary artery hypertrophy is This study provides the first evidence that SERCA2 protein expression levels are re e d dow ow o nr n nreg eg egul ul ulat ated n lung samples from patients with PAH and in cultured proliferating human PASMC and
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S SE SER R RCA2a prot otei ei ein ex xp p pre es essi si sion on on 4 4 45 5 da da day y ys af f fter M M MCT in n nj jec ct cti io on. n. I Im mp mpa a air r red d SE SE S RC RC RCA A A n n 2 2a 2a a a act ct ctiv iv ivit it ity r re resu su ult t ting fr rom om om a a a d dec ecre re reas ase e in in S SE ER RC CA CA2a 2a a e exp xp xpre re ress ssio io on n n ma ma may y th th the er ere ef for r re e be be be i imp mp mpli lica ca ate te ted d i i in f f t the he e p p pat at a ho ho oge ge gene e esi is s of of f nt nt tra ra ratr tr trac ac ach h h PAH. Herein, n, n, w w we e sh sh show ow ow t tha a at t t a a a si ing ng ngle le e i i ea ea e l l l AA AA AAV1 V1 V1.S .S .SER ER ERCA C 2a has de de d li li l ve ve ery ry ry o o of f f ae ae aero ro roso o oli li l ze ze zed d d A A A characterized by proliferation and migration of both PAECs and PASMCs, which is associated with downregulation of SERCA2a in the systemic vasculature. 21 In our study, gene transfer of SERCA2a to restore or maintain SERCA2a levels in proliferating cells exerted beneficial effects by inhibiting activation of the STAT3-NFAT pathway and, thereby, cell proliferation that resulted in near normal vessel morphology. This is consistent with our prior reports that indicated that SERCA2a overexpression inhibits human coronary artery smooth muscle cell proliferation and migration by restoring Ca 2+ homeostasis and increasing the rate of Ca 2+ -store refilling to inhibit store-operated channel-stimulation of PP2B/NFAT signaling. 7 This phenomenon may be supported by the observation that SERCA2a is localized near the nucleus in PASMCs, suggesting that its location may favor a regulatory role for nuclear trafficking of transcription factors such as STAT3 and NFAT. 22 Other studies have found that SERCA2 expression level was diminished in the airway smooth muscle cells in patients with moderately severe asthma, and that SERCA2a downregulation contributed to the airway secretory and hyperproliferative phenotype. 23 Dysregulated proliferation of PASMCs may also be driven by a decrease in PAEC eNOS expression and activation. Our findings confirm prior reports that described a decrease in eNOS expression in MCT PAH rats and are in accordance with observations in lung tissue of patients with PAH patients as compared to control subjects. 24, 25 It is plausible that decreased pulmonary vascular eNOS expression may contribute to pulmonary vasoconstriction and to the excessive medial hypertrophy observed in this PAH. In this study, SERCA2a gene transfer restored eNOS expression in pulmonary arteries compared to what was observed in controls. This finding is also consistent with our prior study that demonstrated that intracoronary AAV1.SERCA2a gene transfer increased endothelial cell eNOS protein expression and activity and improved coronary PASMCs, suggesting that its location may favor f f f a regulatory role for nuclear traf af ff fi fick ck c in in ng g g of of of ranscription factors such as STAT3 and NFAT. 22 Other studies have found that SERCA2 ex xpr pr pres es ssi si sion on n l l lev vel l w w wa as diminished in the airway sm m m oo oth muscle cell ll ls s in n p p pa at atients with moderately e eve e ere r asthma, a a and nd nd t tha ha hat SE SE SERC RC RCA A2 A2a a a d do down wn wnreg gu ul la ati d d o on n c con n ntr tr rib ibu u uted ed e t to o th the e a ai a r rw way ay ay s s sec ecre re eto to ory ry and nd nd hy hype pe perp rp rpro roli life fe fer ra rati tiv v ve p p phe he eno o oty type e e. . 23 23 23 Dysr reg eg egul ul u at at ated ed ed p p pro ro rolife fe fera ra rati ion on on o o of f f PA PA ASM SM SMCs Cs C m m may ay ay a a als lso o o be be be d d dri ri rive ve ven by by by a a a d d dec ec ecre re r as as ase e e in in in P P PAE A C eNOS S S by guest on April 17, 2017 http://circ.ahajournals.org/ Downloaded from blood flow and in a preclinical porcine model of heart failure. 26 Taken together, these observations suggest that SERCA2a gene transfer may play an important role in the control of pulmonary vascular cell proliferation and vessel remodeling.
Recombinant AAV vectors have attracted much interest for clinical gene therapy owing to their safety profile (no known pathology has been found to be associated with AAV in humans), broad tissue tropism, and more importantly, prolonged gene expression without the integration of their DNA into the host chromosome. [27] [28] [29] [30] These vectors have been shown to exhibit less inflammatory and immune reactions than the adenovirus. In this study, we used an AAV serotype 1 vector based on our prior work that demonstrated effective and efficient transduction of endothelial and smooth muscle cells of coronary arteries in vitro and in vivo and long-term expression of our therapeutic protein in heart tissue in human failing hearts. 26, 28, 31 This feature of AAV vectors may be advantageous in investigating the effects of transgenes on chronic disease processes as PAH.
Because AAV1 has tropism for the heart (cardiomyocytes) as well as the endothelium and vascular smooth muscle and we were interested in gene transfer only to the pulmonary vessels, we rationalized that local delivery of AAV1.SERCA2a via a single aerosolized intratracheal instillation would limit off-target transduction of the heart. The use of intratracheal aerosol delivery for pulmonary gene transfer has been described previously using adenovirus. ong-term expression of our therapeutic protein in heart tissue in . human failing hearts 26, 28, 31 This fe eat at tur ur ure e e of of of A A AAV A A v v ve ec ectors may be advantageous in n n i i inv nv vestigating the e ef e fe ect ct cts s s of transgenes on h ch hro o oni n c diseas se e p p pro oc oces es sse e es s a as as P P PAH AH AH. . .
Be Beca ca cau us use e AA AA AV V1 1 h h has as t tro ro r pi pi pism sm sm f for or r t the he he h h hea a art rt r ( ( (ca a ard rd dio iomy my myoc oc cyt yt y e e es) ) as as a w w we el ell l as as as t t the he h e e end n ndot ot the e eli lium um m and vascular r s s smo mo m ot ot oth h h mu mu musc cle le le a a and nd d w w we e e we we ere re re i int nt n er er e e e e st st ted ed ed i in n ge ge gene ne ne t tra ra rans ns nsfe e er r r on on only ly ly t t to o o th th he e e pu pu pulm lm lmon o ary by guest on April 17, 2017 http://circ.ahajournals.org/ Downloaded from the lungs of subjects with cystic fibrosis was safe and well tolerated. 33 There are few experimental studies that have trialed adeno-associated virus (AAV) for therapeutic gene transfer in pulmonary hypertension with only 2 prior studies using an intranasal or intratracheal aerosol route for AAV delivery in PAH models. 34, 35 In these studies, however, the AAV serotype was not divulged and it is, therefore, difficult to interpret the findings reported without this information. Other studies that have performed gene transfer of AAV1 or AAV2 in rodent models of PAH have utilized an intramuscular injection delivery approach. 36-38 39, 40 In these studies, there is likely off-target gene transfer throughout the cardiovascular system and it would be difficult to determine if favorable pulmonary hemodynamics resulted from an improvement in pulmonary vascular remodeling and/or direct transduction of the RV.
Although gene transfer of SERCA2a to the RV was not an aim of this study, it is plausible that future therapeutic interventions in established PAH with RV failure may combine directed pulmonary vascular and RV transduction. It has been shown that in isolated cardiomyocytes and animal models of left heart failure that restoring SERCA2a expression by gene transfer corrects contractile abnormalities, improves energetic and electrical remodeling, and improves hemodynamic function along with survival in rodent and large animal models of heart failure. 41, 42 The overall beneficial profile of SERCA2a targeting has led to the initiation and successful completion of a first-in-human gene therapy trial (CUPID) to investigate the effects of AAV1-SERCA2a gene transfer in patients with heart failure. [28] [29] [30] In conclusion, our study demonstrates that selective pulmonary vascular gene transfer of SERCA2a with aerosolized AAV1.SERCA2a modulates hypertrophic vascular remodeling in established PAH to lower pulmonary pressures and adverse right ventricular remodeling.
Furthermore, maintaining pulmonary vascular SERCA2a expression prevents pulmonary arterial pulmonary vascular remodeling and/or direct transduction of the RV. r
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